TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34845300
Drug: Ranibizumab intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab intravitreal injections (both groups)
Study: 34845868
Drug: Levetiracetam (1,000-2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1,000-2,000 mg daily in two divided doses during CCRT and adjuvant chemotherapy)
Study: 34845917
Drug: Cluster 3
Normalized name: CLUSTER FIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster 3 (middle-aged/lowest medication adherence)
Study: 34845924
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of EPA+DHA >200 mg/d
Study: 34845924
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of EPA+DHA ≤50 mg/d
Study: 34845924
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of EPA+DHA per 100 mg/d
Study: 34846614
Drug: Laparoscopic TME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic TME (L-TME)
Study: 34848522
Drug: 330 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mL/d of orange juice (OJ)
Study: 34848522
Drug: Control drinks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drinks with and without hesperidin (approx. 200-215 mg)
Study: 34848527
Drug: Immersive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive virtual reality (VR) therapy
Study: 34849677
Drug: IL-6 concentrations
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 concentrations ≥ median (17 ng/L)
Study: 34849728
Drug: Theophylline (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (starting dose 300 mg b.i.d.)
Study: 34851726
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Study: 34852305
Drug: High-intensity bridging
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity bridging chemotherapy (≥2 cycles)
Study: 34852305
Drug: Low-intensity bridging
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity bridging chemotherapy (1 cycle)
Study: 34852305
Drug: Bridging chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging chemotherapy (both intensities)
Study: 34853082
Drug: Optimised preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised preventive treatment strategy (treating arteries instead of risk factors)
Study: 34853376
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous access iohexol GFR measurement
Study: 34853376
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous access iohexol GFR measurement after blood discarding and saline flushing
Study: 34853376
Drug: Blood sampling
Normalized name: TERUFLEX Blood with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative for Collection of 450mL of Blood KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood sampling from a second intravenous access
Study: 34853511
Drug: Anti-inflammatory anti-diabetic
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory anti-diabetic medication (including metformin)
Study: 34853511
Drug: Metformin-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-containing therapy
Study: 34853511
Drug: Oral anti-diabetic
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-diabetic medication (overall)
Study: 34854079
Drug: high-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose dexamethasone (HD-DXM)
Study: 34854079
Drug: standard-dose rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard-dose rituximab
Study: 34854079
Drug: low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose rituximab
Study: 34854418
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rate at 3 L/min with HME attached
Study: 34854418
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rate at 6 L/min with HME attached
Study: 34854418
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rate at 3 L/min without HME
Study: 34854418
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rate at 6 L/min without HME
Study: 34854418
Drug: HME (+)
Normalized name: TRACH-VENT HME TELEFLEX #41112
Approvals — FDA: no, EMA: no, PMDA: no
Description: HME (+) regardless of anesthetic agent
Study: 34854418
Drug: HME (-)
Normalized name: TRACH-VENT HME TELEFLEX #41112
Approvals — FDA: no, EMA: no, PMDA: no
Description: HME (-) regardless of anesthetic agent
Study: 34854818
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with the Pfizer vaccine
Study: 34855649
Drug: Short-term psychopharmacological
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychopharmacological treatment (12 weeks)
Study: 34857214
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iron Absorption Test (OIAT) combined with Oral Glucose Tolerance Test (OGTT) measuring ΔSeFe after an oral iron dose of 6 mg.
Study: 34857214
Drug: Fractional Iron
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional Iron Absorption (FIA) using stable iron isotopes from a labeled iron dose.
Study: 34857214
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iron Absorption Test (OIAT)
Study: 34857432
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at 396 days post-MI
Study: 34857432
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at 5 years post-MI
Study: 34857432
Drug: DAPT use
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT use in relation to age and treatment type
Study: 34857473
Drug: Management including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management including medical treatment and secondary revascularization (SR)
Study: 34857585
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion during liver transplantation surgery
Study: 34857585
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion during liver transplantation surgery
Study: 34857658
Drug: urokinase-type plasminogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: urokinase-type plasminogen activator receptor (uPAR) PET/CT
Study: 34858178
Drug: Immunotherapy combined
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy combined with antiangiogenic therapy
Study: 34858423
Drug: Dendritic Cell-Based
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic Cell-Based HIV Vaccine in combination with Pegylated Interferon α-2a
Study: 34858523
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (gln) powder 15 g bid for the full duration of treatment
Study: 34858829
Drug: neoadjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant concurrent chemoradiotherapy (nCRT)
Study: 34859113
Drug: Perioperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative administration of cefazolin, vancomycin, bacitracin, and cephalexin
Study: 34860120
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection
Study: 34860418
Drug: High-dose LNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose LNF (≥75 mg po bid + RTV) for 12 weeks
Study: 34860418
Drug: All-oral low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All-oral low-dose LNF (25 or 50 mg po bid + RTV) for 24 weeks
Study: 34860418
Drug: Combination low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination low-dose LNF (25 or 50 mg po bid + RTV + PEG-IFNα) for 24 weeks
Study: 34860739
Drug: Iopromide administration
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopromide administration in children
Study: 34860739
Drug: Iopromide administration
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopromide administration in elderly
Study: 34860739
Drug: Iopromide administration
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopromide administration in adults
Study: 34862245
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line (given weekly for 4 weeks, then every 8 weeks until depletion or disease progression)
Study: 34862245
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line
Study: 34862302
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) performed by a CBT-trained cardiac nurse plus usual care
Study: 34863019
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Folinic Acid and Thyroid Hormone)
Study: 34863019
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups pooled for post-hoc analysis
Study: 34863025
Drug: IgG3 donor-specific
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG3 donor-specific antibodies (dnDSA) from ABMR+ patients
Study: 34863025
Drug: IgG3 donor-specific
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG3 donor-specific antibodies (dnDSA) from ABMR- patients
Study: 34863120
Drug: Passive manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive manual therapy mobilizations
Study: 34863122
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection waves including clinical, socio-behavioral, biological data, and in-depth interviews
Study: 34863216
Drug: velaglucerase alfa
Normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: velaglucerase alfa 60 U/kg every 2 weeks via intravenous infusion
Study: 34863258
Drug: C1-inhibitor (C1-INH)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (C1-INH) 6000 IU
Study: 37488627
Drug: Sound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound therapy
Study: 34864883
Drug: Univariate analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Univariate analysis of sociodemographic, injury-related, treatment, and early hospital outcome variables
Study: 34864948
Drug: Ledipasvir/Sofosbuvir (90mg/400mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir (90mg/400mg) once daily for 12 weeks
Study: 34865085
Drug: Amitriptyline, Topiramate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline, Topiramate, or Placebo (twice daily)
Study: 34865085
Drug: Serum drug
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum drug levels
Study: 34865085
Drug: Self-report and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-report and pill count adherence
Study: 34865085
Drug: Serum drug
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum drug levels at trial midpoint
Study: 34867148
Drug: Carriers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carriers of Val/Met (G/A) or Met (A/A) alleles
Study: 34867148
Drug: Homozygous Val
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homozygous Val (G/G) carriers
Study: 34868050
Drug: 81mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81mg of ASA daily for 6 weeks
Study: 34869938
Drug: Composite intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite intervention including non-hormonal pharmacotherapy for VMS, digital cognitive behavioural therapy for insomnia, self-management strategies, and partner support
Study: 34870025
Drug: Prenatal plus
Normalized name: Prenatal Plus
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prenatal plus postnatal small-quantity lipid-based nutrient supplements (SQ-LNS)
Study: 34870878
Drug: Xentuzumab 750
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xentuzumab 750 mg/wk
Study: 34870878
Drug: Xentuzumab 1000
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xentuzumab 1000 mg/wk
Study: 34870878
Drug: Xentuzumab 1000
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xentuzumab 1000 mg/wk (expansion cohort)
Study: 34871089
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) at 25 mg once daily plus two investigator-selected NRTIs
Study: 34871178
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention at individual, team, and organizational levels; specific details on dosage and duration not provided.
Study: 34871427
Drug: Sorghum diet
Normalized name: Sorghum
DrugBank: Sorghum (DB17914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorghum diet with lysine levels of 8.2, 12.5, and 15.7 mg.kg-1.d-1
Study: 34871427
Drug: Reference diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference diet with L-lysine levels of 5, 8, 12, and 15 mg.kg-1.d-1
Study: 34871570
Drug: Tafenoquine 100
Normalized name: tafenoquine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 100 mg
Study: 34871570
Drug: Tafenoquine 150
Normalized name: tafenoquine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 150 mg
Study: 34871570
Drug: Tafenoquine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 200 mg
Study: 34872515
Drug: Standard anti-NTM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-NTM treatment initiated within 3 months after diagnosis of NTM pulmonary disease
Study: 34872549
Drug: Two-item swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-item swallowing screen (oral stereognosis and cough-reflex tests)
Study: 34873345
Drug: Avapritinib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib, a selective KIT D816V inhibitor, starting dose of 200 mg once daily
Study: 34873347
Drug: Avapritinib (BLU-285)
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Avapritinib (BLU-285) at doses of 30-400 mg once daily
Study: 34873975
Drug: Trilaciclib prior
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib prior to chemotherapy
Study: 34874228
Drug: Geriatric assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric assessment (GA) including modified GA (mGA) assessing comorbidities, medications, nutritional status, basic- and instrumental activities of daily living (IADL), mobility, falls, cognition, and depressive symptoms.
Study: 34875111
Drug: Intermediate-dose thromboprophylaxis
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose thromboprophylaxis
Study: 34875909
Drug: Cluster 1
Normalized name: CLUSTER FIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster 1 (optimal oral health and preserved masticatory capacity)
Study: 34875909
Drug: Cluster 2
Normalized name: CLUSTER FIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster 2 (moderate oral health and moderately impaired masticatory capacity)
Study: 34875909
Drug: Cluster 3
Normalized name: CLUSTER FIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster 3 (poor oral health and severely impaired masticatory capacity)
Study: 34876196
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) antibiotics
Study: 34876408
Drug: CART therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART therapy targeting BCMA, fractioned dose of 3×10
Study: 34876409
Drug: Atezolizumab 1,200
Normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1,200 mg every 3 weeks
Study: 34876419
Drug: Isocaloric toddler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric toddler milk with 1.5 g/100 kcal protein
Study: 34876419
Drug: Isocaloric toddler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric toddler milk with 6.15 g/100 kcal protein (control)
Study: 34876420
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin hydrochloride, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Study: 34876420
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matching the active study drug, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Study: 34876429
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT)-based mobile app
Study: 34876434
Drug: ATG (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg)
Study: 34877470
Drug: Non-FMT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-FMT treatment
Study: 34878437
Drug: Probiotics (five-strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (five-strain probiotic capsules, 1.2 × 10^10 CFUs/d for 8 weeks)
Study: 34878898
Drug: Lead levels
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead levels in quartile four (≥6.5 µg/dL)
Study: 34878898
Drug: Lead levels
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead levels in quartile one (<3.4 µg/dL)
Study: 34879833
Drug: Neopterin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neopterin (in combination with KA)
Study: 34880013
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of autologous ex vivo expanded regulatory T cells (Treg)
Study: 34880117
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (ESIs) for sciatica
Study: 34882570
Drug: Intranasal racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal racemic ketamine hydrochloride administered twice per week for 4 weeks (8 sessions)
Study: 34882570
Drug: Intranasal racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal racemic ketamine hydrochloride
Study: 34882589
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (3 µg intramuscular doses, two doses 28 days apart)
Study: 34882831
Drug: Once-weekly selinexor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly selinexor, bortezomib, and dexamethasone
Study: 34882831
Drug: Standard twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard twice-weekly bortezomib and dexamethasone
Study: 37365439
Drug: Daily Examen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Examen
Study: 34886910
Drug: Home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapy group (HT group) directed by surgeons at post-operative appointments
Study: 34886909
Drug: Remote nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote nutrition monitoring intervention with tailored nutritional counseling before and after surgery at 2 and 4 weeks after hospital discharge. Participants recorded nutritional intake daily for 30 days, reviewed by registered dietitians.
Study: 34887051
Drug: PTX drug-coated
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX drug-coated balloon angioplasty
Study: 34887051
Drug: PTX drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX drug-eluting stent therapy
Study: 34887574
Drug: Immune-modulatory vaccine
Normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-modulatory vaccine (IO102/IO103) combined with nivolumab
Study: 34887772
Drug: Evolocumab added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab added to moderate-intensity statin therapy